Needham Maintains Buy on Cormedix, Lowers Price Target to $12
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.